Tris Pharma Announces Development of a Very Low Sodium and Once-Nightly Oxybate Formulation
Retrieved on:
Wednesday, July 27, 2022
Ketan, Somnolence, Time, Absorption, Multiple sclerosis, Hess, EDS, Jazz Pharmaceuticals, Trial of the century, Narcolepsy, Classification, List of Hindawi academic journals, Hallucination, Incidence, GM, Kingsley v. Hendrickson, CNS, Spasticity, Knowledge Organization (journal), Excessive daytime sleepiness, Epidemiology, Cataplexy, Sleep, ADHD, Wakefulness, Patient, Sodium, Cerebral palsy, Pain, Emotion, Hypertension, Heart failure, Sleep paralysis, Sodium oxybate, Prevalence, Neurological disorder, Pharmaceutical industry, Tris
The Tris oxybate formulation is believed to provide an advantage over approved therapies by utilizing Tris's proprietary LiquiXR technology platform and our newly developed RaftWorks design to provide a unique oxybate formulation offering both once-nightly dosing, and very low sodium content.
Key Points:
- The Tris oxybate formulation is believed to provide an advantage over approved therapies by utilizing Tris's proprietary LiquiXR technology platform and our newly developed RaftWorks design to provide a unique oxybate formulation offering both once-nightly dosing, and very low sodium content.
- The Tris oxybate formulation seeks to improve on existing therapies by providing convenient once per night dosing, and significantly reduced sodium content such that it will contain less than 100 mg of sodium per 9.0 gm of maximum sodium oxybate equivalent dose.
- Based on the significant potential advantage the Tris oxybate formulation could provide over existing available therapies, Tris is pursuing an Orphan Drug Designation for its unique oxybate formulation.
- The Tris oxybate product achieved its clinical objectives by combining two distinct proprietary Tris technologies: the LiquiXR platform, and the newly developed RaftWorks design.